Loading...
Market
What will be the outcome of the first clinical trial for IL-7 as a treatment for Celiac Disease?
2
Resolution / Starting Odds
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trial terminated early • 25%
ClinicalTrials.gov, official publications of trial results
Story
NIAID-Funded Researchers, StanfordMed Identify IL-7 as Potential Treatment Target for Celiac Disease in Nature
Jul 25, 2024, 11:10 AM
Researchers funded by the National Institute of Allergy and Infectious Diseases (NIAID) have developed an organoid model of Celiac Disease that replicates the tissue structure and immune features of the human intestine. This model, credited to StanfordMed, has identified Interleukin-7 (IL-7) as a potential treatment target. IL-7 is a gluten-inducible pathogenic modulator that regulates CD8+ T-cell NKG2C/D expression and is necessary for epithelial destruction in the gut. The findings, published in Nature, highlight a new link between gluten and intestinal damage, providing a promising direction for future Celiac Disease therapies.
View original story
Similar markets
Completed with positive results • 25%
Completed with negative results • 25%
Not completed • 25%
Unknown/Other • 25%
Successful completion of Phase 1 • 25%
Partial success in Phase 1 • 25%
Failure in Phase 1 • 25%
No results announced • 25%
Lifespan Extension • 25%
Cancer Reduction • 25%
Gray Hair Reduction • 25%
Other • 25%
Initiated before January 1, 2025 • 25%
Initiated between January 1, 2025 and March 31, 2025 • 25%
Initiated between April 1, 2025 and June 30, 2025 • 25%
Not initiated by June 30, 2025 • 25%
Yes • 50%
No • 50%
Phase 1 • 25%
Phase 2 • 25%
Phase 3 • 25%
Phase 4 • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Phase 1 • 25%
Phase 2 • 25%
Phase 3 • 25%
Approved • 25%
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trial halted • 25%